The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Marc Frahm, an analyst at TD Cowen, downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) from Buy to Hold. This ...

This happened after Sanofi announced plans to buy the company for $9.1 billion in stock value and up to $9.5 billion in ...

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

Sanofi has agreed to purchase Blueprint Medicines for $129.00 per share in cash, valuing the deal at $9.1 billion, marking a 27.3% premium over Blueprint’s closing share price last Friday.

Sanofi and Blueprint Medicines Corporation have entered into an agreement under which Sanofi plans to acquire the US biopharmaceutical company Blueprint for 9.1 billion dollars.

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

Sanofi to acquire US-based biopharma company, Blueprint Medicines for up to $9.5 billion: Paris Tuesday, June 3, 2025, 09:00 Hrs [IST] Sanofi and Blueprint Medicines Corporation ( ...

French drugmaker adds Ayvakit and next-gen immunology pipeline in strategic move to dominate rare disease space Sanofi has ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...

The French drugmaker has acquired Blueprint Medicines Corporation following its sale of health consumer brand Opella.